1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
LTR Pharma Limited

LTR Pharma Limited

LTP.AX
LTR Pharma LimitedAU flagAustralian Securities Exchange
0.44
AUD
- -
- -
80.20MMarket Cap
LTR Pharma Limited
LTP.AX
(Australian Securities Exchange)

Recent

price

0.44

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.01
-0.01
-0.05
-0.03
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
0.01
0.05
0.02
0.17
Book Value per Share
- -
0.01
0.05
0.02
0.17
Tangible Book Value per Share
139
139
139
139
167
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
-5,123.89
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-1
-7
-6
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-3,837.01
Profit Margin (%)
- -
1
7
3
31
Working Capital
- -
- -
- -
- -
- -
LT Debt
- -
2
7
3
32
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-31.43
-133.37
-32.47
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
971.58%
Free Cash Flow
- -
- -
566.4%
Net Income, GAAP
- -
- -
-19.57%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.05
2025
- -
- -
- -
- -
-0.03

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Ceapro Inc. (CZO.V)
Whitehawk Therapeutics Inc (WHWK)
Sinocelltech Group Limited (688520.SS)
Feng Chi Biotech Corp. (6744.TWO)
iBio, Inc. (IBIO)
Kuros Biosciences AG (CSBTF)
Business
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.